Product Pipeline

Primary Areas of Focus

Our clinical research is focused on identifying ways to improve vascular health and healing which can positively impact millions of patients globally.

limb-leg-long-1
Peripheral Arterial Disease (PAD)

236 million affected globally

A marker of atherosclerosis, people with PAD are at increased risk of heart attack, stroke, CV death and functional decline. 10% progress to CLTI with amputation risk, severely limiting mobility and independence

Symptoms: Leg pain during walking, cramping or burning, rest pain in the feet or toes, numbness, slow-healing wounds

heart
Cardiomyopathy

Millions with refractory symptoms

A disease of the heart muscle where the myocardium becomes structurally and functionally abnormal, making it harder for the heart to pump blood or relax to fill properly. Cardiomyopathy patients are at increased risk of heart failure, sudden CV death, blood clots and other severe complications.

Symptoms: Shortness of breath, fatigue, palpitations, swelling. 

limb-leg-long-1
Chronic Limb-Threatening Ischemia (CLTI)

900k New CLI patients annually

A severe progression of PAD due to significant blockage in the arteries of the legs or feet, 20-40% amputation rate within 5 years, 50% mortality rate, chronic pain and disability

Symptoms: Severe pain, coldness, ulcers or gangrene: Tissue death (necrosis) on the toe, or foot, often appearing black, dry, or infected.

heart
Congestive Heart Failure

64 Million affected worldwide. 8.7M in the US by 2030

A chronic, progressive disease limiting the heart muscle's ability to pump blood effectively enough to meet the body's needs. 50% five-year mortality rate and the primary cause of hospitalizations annually in the US/Europe (2m+ Annually)

Symptoms: Severe fatigue, fluid retention and weight gain, breathlessness even at rest, fatigue and swelling.

Clinical Trials Image